Amgen Inc. (AMGN)
NASDAQ • Healthcare
November 17, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Amgen Inc. keeps $37 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 2
in 76 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Amgen beat consensus on both the top and bottom line in the second fiscal quarter of 2026, reported on August 4 based on preliminary results, with revenue of about $10.1 billion topping the about $9.4 billion estimate by 7% and adjusted EPS of $6.29 beating the $5.64 consensus by 12%. Revenue rose 10% from about $9.2 billion a year ago, while net income climbed 66% to about $2.4 billion from about $1.4 billion and adjusted EPS was up 5% from $6.02. Operating income reached about $3.5 billion as operating margin held about 35%, with gross margin near 72%. Operating cash flow was about $4.0 billion, the company paid about $1.4 billion in dividends, and consensus for the next period calls for EPS of $5.77 on revenue of $9.72 billion.
About Amgen Inc.
Amgen Inc. develops, manufactures, and delivers human medicines as a large-cap biotechnology and biopharmaceutical company listed on NASDAQ as AMGN. Its portfolio spans inflammation, cancer and blood disorders, bone health, cardiovascular disease, kidney-related care, and neuroscience, and it generated $36.7 billion of revenue in FY2025.
Today's Snapshot
AMGN closed 0.9% below yesterday's close, in line with a weaker sector. Amgen raised its 2026 forecasts twice, saying it expects stronger results.
Trading Volume
Below 10d avg (2.6M)
2M
vs S&P 500 Today
Moderate Outperformance
+0.40%
Updated: November 17, 2026 at 21:16 UTC
AMGN Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$387.47 - $462.26Buy
- RSI (14)55.31Neutral
- Stochastic %K (14, 3, 3)46.57Neutral
- MACD Level (12, 26)9.78Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.